Welcome to our dedicated page for Minerva Neurosci news (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosci stock.
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company developing product candidates for central nervous system (CNS) disorders, with a lead focus on roluperidone for negative symptoms of schizophrenia. The NERV news feed on Stock Titan aggregates company-issued updates and market-moving disclosures so readers can follow how Minerva’s clinical, regulatory and financing milestones evolve over time.
Recent news from Minerva highlights its ongoing interactions with the U.S. Food and Drug Administration (FDA) following a Complete Response Letter to its New Drug Application for roluperidone, as well as the agency’s requirement for a confirmatory Phase 3 trial. The company has released details about the planned trial design, including patient selection criteria, dosing, and the primary efficacy endpoint based on the PANSS Marder negative symptoms factor score.
Investors tracking NERV can also find announcements about Minerva’s private placement financing involving Series A Convertible Preferred Stock and warrants, which the company expects to use to fund the confirmatory Phase 3 study, NDA resubmission, and preparation for a potential U.S. commercial launch of roluperidone, if approved. Additional news items cover quarterly and annual financial results, changes in research and development and general and administrative expenses, and updates on the company’s cash position.
Governance and leadership developments appear in the news flow as well, including the appointment of new directors with schizophrenia clinical trial experience and a consulting agreement intended to support roluperidone’s late-stage development. For readers interested in CNS drug development, regulatory strategy, and biotech financing structures, the NERV news page provides a centralized view of Minerva’s public communications. Bookmark this page to review new press releases, earnings updates and material 8-K disclosures as they are reported.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Minerva Neurosciences, Inc. (Nasdaq: NERV) reported its Q4 and full-year 2022 financial results and business updates. The company experienced a net loss of $6.7 million in Q4 2022, significantly down from a loss of $21.3 million in Q4 2021. The annual net loss was $32.1 million, compared to $49.9 million in 2021. Research and development expenses decreased to $3.2 million in Q4 from $18.7 million, largely due to a prior year impairment charge. Cash reserves were approximately $36.2 million as of December 31, 2022. The company remains focused on the regulatory path for its lead drug, roluperidone, which faced a Refuse to File letter from the FDA last fall, indicating ongoing dialogue with the agency.